28 Mar, 2018 Online vs Community pharmacies By Robert Newman It is going to be interesting to watch the continued tussle between the online and community pharamacy sectors. Both offer convincing...
22 Mar, 2018 Consolidation is the name of the game for our public healthcare system By Caroline Scott Very interesting article about the vision of the NHS to transform and consolidate our public healthcare system to drive further...
21 Mar, 2018 Webinar discussing the fallout from the up coming EU summit and what it may mean to businesses in areas such as the Life Sciences. By Mark Franklin Join members of DLA Piper's Brexit Committee for a webinar hosted right after this weeks EU summit ends. They will cut through the noise...
19 Mar, 2018 Some Brexit clarity.....to end of 2020 By DLA Piper A Brexit transition period to 31 December 2020 is good news for the Life Sciences industry. Brexit negotiators have now agreed Article...
13 Mar, 2018 Publishing Clinical Data under Policy 0070 By DLA Piper We have been looking closely at the EMA requirements for publishing clinical data under Policy 0070. There is an expanding body of...
12 Mar, 2018 What’s in a name? The Latest Considerations in Naming Biosimilars By Roberto Valenti Really looking forward to meeting you at the IP Forum for Life Sciences in April. I will be hosting a discussion with tregard to naming...
06 Mar, 2018 Northern Powerhouse going global By DLA Piper Tomorrow I will be on stage at 11 am discussing 'Growing Global' at the Northern Powerhouse Health Innovation Conference 2018. The first...
06 Mar, 2018 Pharma and biotech legal developments - C5 conference report By DLA Piper I spent two fascinating days at the C5 Pharma and biotech conference last week. Some of the more interesting takeaways: in determining...